Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma

Takata,Hideyuki; Kudo,Mitsuhiro; Yamamoto,Tetsushi; Ueda,Junji; Ishino,Kousuke; Peng,Wei‑Xia; Wada,Ryuichi; Taniai,Nobuhiko; Yoshida,Hiroshi; Uchida,Eiji; Naito,Zenya

doi:10.3892/ol.2016.5304

Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma

Authors:
- Hideyuki Takata
- Mitsuhiro Kudo
- Tetsushi Yamamoto
- Junji Ueda
- Kousuke Ishino
- Wei‑Xia Peng
- Ryuichi Wada
- Nobuhiko Taniai
- Hiroshi Yoshida
- Eiji Uchida
- Zenya Naito
View Affiliations

Affiliations: Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113‑8602, Japan, Faculty of Pharmacy, Kinki University, Osaka 577‑8502, Japan, Department of Gastrointestinal Hepato‑Biliary‑Pancreatic Surgery, Nippon Medical School, Tokyo 113‑8602, Japan
Published online on: October 21, 2016 https://doi.org/10.3892/ol.2016.5304
Pages: 4896-4904
Copyright: © Takata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of hepatocellular carcinoma (HCC) is unfavorable following complete tumor resection. The aim of the present study was to identify a molecule able to predict HCC prognosis through comprehensive protein profiling and to elucidate its clinicopathological significance. Comprehensive protein profiling of HCC was performed by liquid chromatography‑tandem mass spectrometry. Through the bioinformatic analysis of proteins expressed differentially in HCC and non-HCC tissues, protein disulfide-isomerase A3 (PDIA3) was identified as a candidate for the prediction of prognosis. PDIA3 expression was subsequently examined in 86 cases of HCC by immunostaining and associations between PDIA3 expression levels and clinicopathological characteristics were evaluated. The Ki‑67 index and apoptotic cell death of carcinoma cells were examined by immunostaining and terminal deoxynucleotidyl transferase dUTP nick‑end labeling assay in 24 cases. The results demonstrated that PDIA3 was expressed in all 86 HCC cases; 56 HCC cases (65%) exhibited high expression of PDIA3 and 30 (35%) exhibited low expression. The disease‑free and overall survival times of HCC patients with high PDIA3 expression were significantly shorter than in HCC patients with low expression. Furthermore, increased expression of PDIA3 was associated with an elevated Ki‑67 index, indicating increased cancer cell proliferation and a reduction in apoptotic cell death. Taken together, these results suggest that PDIA3 expression is associated with tumor proliferation and decreased apoptosis in HCC, and that increased expression of PDIA3 predicts poor prognosis. PDIA3 may therefore be a key molecule in the development of novel targeting therapies for patients with HCC.

View Figures

View References

1	Mittal S and El-Serag HB: Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol. 47:(Suppl). S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
2	Roxburgh P and Evans TR: Systemic therapy of hepatocellular carcinoma: Are we making progress? Adv Ther. 25:1089–1104. 2008. View Article : Google Scholar : PubMed/NCBI
3	de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol. 56:(Suppl 1). S75–S87. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
5	Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR and Berry DP: Prognostic molecular markers in hepatocellular carcinoma: A systematic review. Eur J Cancer. 43:979–992. 2007. View Article : Google Scholar : PubMed/NCBI
6	Poon RT: Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology. 54:757–759. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chignard N, Shang S, Wang H, Marrero J, Bréchot C, Hanash S and Beretta L: Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology. 130:2010–2022. 2006. View Article : Google Scholar : PubMed/NCBI
8	Corona G, De Lorenzo E, Elia C, Simula MP, Avellini C, Baccarani U, Lupo F, Tiribelli C, Colombatti A and Toffoli G: Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol. 36:93–99. 2010.PubMed/NCBI
9	Huang X, Zeng Y, Xing X, Zeng J, Gao Y, Cai Z, Xu B, Liu X, Huang A and Liu J: Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci. 12:222014. View Article : Google Scholar : PubMed/NCBI
10	Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K, Ueda T and Kaneko S: Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta. 1784:764–772. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yokoo H, Kondo T, Okano T, Nakanishi K, Sakamoto M, Kosuge T, Todo S and Hirohashi S: Protein expression associated with early intrahepatic recurrence of hepatocellular carcinoma after curative surgery. Cancer Sci. 98:665–673. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gustafsson OJ, Arentz G and Hoffmann P: Proteomic developments in the analysis of formalin-fixed tissue. Biochim Biophys Acta. 1854:559–580. 2015. View Article : Google Scholar : PubMed/NCBI
13	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
14	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
15	Zybailov B, Coleman MK, Florens L and Washburn MP: Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal Chem. 77:6218–6224. 2005. View Article : Google Scholar : PubMed/NCBI
16	Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, Resing KA and Ahn NG: Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 4:1487–1502. 2005. View Article : Google Scholar : PubMed/NCBI
17	da W Huang, Sherman BT, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID gene ID conversion tool. Bioinformation. 2:428–430. 2008. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Paulsson K and Wang P: Chaperones and folding of MHC class I molecules in the endoplasmic reticulum. Biochim Biophys Acta. 1641:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
20	Turano C, Gaucci E, Grillo C and Chichiarelli S: ERp57/GRP58: A protein with multiple functions. Cell Mol Biol Lett. 16:539–563. 2011. View Article : Google Scholar : PubMed/NCBI
21	Celli CM and Jaiswal AK: Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res. 63:6016–6025. 2003.PubMed/NCBI
22	Chay D, Cho H, Lim BJ, Kang ES, Oh YJ, Choi SM, Kim BW, Kim YT and Kim JH: ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. Int J Oncol. 37:399–412. 2010.PubMed/NCBI
23	Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, Lai CH, Liang Y, Jung SM and Lin KH: Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 102:2255–2263. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chung H, Cho H, Perry C, Song J, Ylaya K, Lee H and Kim JH: Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. Biomarkers. 18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
25	Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E and Goldenring JR: Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 141:41–50. 2007. View Article : Google Scholar : PubMed/NCBI
26	Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, Redfern CP and Piacentini M: Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: The role of stress proteins ERdj5 and ERp57. Br J Cancer. 96:1062–1071. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ramírez-Rangel I, Bracho-Valdés I, Vazquez-Macías A, Carretero-Ortega J, Reyes-Cruz G and Vázquez-Prado J: Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. Mol Cell Biol. 31:1657–1671. 2011. View Article : Google Scholar : PubMed/NCBI
28	Matter MS, Decaens T, Andersen JB and Thorgeirsson SS: Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. J Hepatol. 60:855–865. 2014. View Article : Google Scholar : PubMed/NCBI
29	Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y and Jia X: Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 31:1449–1456. 2013.PubMed/NCBI